Long-term survival after treatment of gastric cancer with S-1 plus oxaliplatin regimen and sintilimab: A case report.
[BACKGROUND] Treatment of metastatic gastric cancer (mGC) relies primarily on chemotherapy, which can be effectively combined with immunotherapy.
APA
Pan J, Li P, et al. (2025). Long-term survival after treatment of gastric cancer with S-1 plus oxaliplatin regimen and sintilimab: A case report.. World journal of gastrointestinal oncology, 17(12), 112853. https://doi.org/10.4251/wjgo.v17.i12.112853
MLA
Pan J, et al.. "Long-term survival after treatment of gastric cancer with S-1 plus oxaliplatin regimen and sintilimab: A case report.." World journal of gastrointestinal oncology, vol. 17, no. 12, 2025, pp. 112853.
PMID
41480201
Abstract
[BACKGROUND] Treatment of metastatic gastric cancer (mGC) relies primarily on chemotherapy, which can be effectively combined with immunotherapy. Despite these interventions, overall survival remains suboptimal.
[CASE SUMMARY] We report a patient with mGC who received S-1 plus oxaliplatin with sintilimab as first-line therapy, followed by maintenance therapy with S-1 and sintilimab. After 6 months, a partial response was observed, with a 71.7% reduction in the target lesion. After 13 months, the reduction reached 76.3%. Treatment was temporarily paused for 6 months due to a pulmonary infection. Upon re-evaluation 6 months later, the tumor continued to regress, with a 79.4% reduction in the target lesion. The original regimen was then resumed. From diagnosis to date, progression-free survival has reached 23 months.
[CONCLUSION] Sintilimab combined with chemotherapy demonstrated improved progression-free survival and warrants further investigation in mGC.
[CASE SUMMARY] We report a patient with mGC who received S-1 plus oxaliplatin with sintilimab as first-line therapy, followed by maintenance therapy with S-1 and sintilimab. After 6 months, a partial response was observed, with a 71.7% reduction in the target lesion. After 13 months, the reduction reached 76.3%. Treatment was temporarily paused for 6 months due to a pulmonary infection. Upon re-evaluation 6 months later, the tumor continued to regress, with a 79.4% reduction in the target lesion. The original regimen was then resumed. From diagnosis to date, progression-free survival has reached 23 months.
[CONCLUSION] Sintilimab combined with chemotherapy demonstrated improved progression-free survival and warrants further investigation in mGC.
같은 제1저자의 인용 많은 논문 (5)
- CAD manipulates tumor intrinsic DHO/UBE4B/NF-κB pathway and fuels macrophage cross-talk, promoting HCC metastasis.
- Immunotherapy-driven remodeling of the tumor immune microenvironment: Spatiotemporal heterogeneity and multidimensional dynamics.
- Cannabidiol suppresses emergency MDSCs generation by disturbing EEF1B2-mediated C/EBP protein synthesis in colorectal adenomas.
- Protective Effect of Red Yeast Rice on Immune Checkpoint Inhibitors-Related Atherosclerotic Progression Through Inhibiting Macrophage Inflammatory Response and T Lymphocytes Infiltration.
- U-shaped association of red cell distribution width to platelet count ratio and prognosis in diffuse large B-cell lymphoma treated with rituximab-based therapy.